high mobility group nucleosomal binding domain 2 pseudogene 19Genealiases: []
Q-omics provides the consensus-scored HMGN2P19 profile across patient tissues and cancer cell-line models. HMGN2P19 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HMGN2P19 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, HMGN2P19 RNA expression shows 9,213 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight HNSC, BLCA, and SARC as cancer lineages where HMGN2P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN2P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN2P19 survival associations across molecular data types. HMGN2P19 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN2P19 RNA expression–survival associations across cancer types. High HMGN2P19 expression shows unfavorable associations in HNSC, LGG, ESCA and STAD, but favorable associations in COAD and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for HMGN2P19 RNA expression.
This table summarizes HMGN2P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN2P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN2P19 shows lower tumor expression in BLCA, THCA, BRCA, KICH, COAD and LUSC. The BLCA box plot shows higher HMGN2P19 RNA expression in normal versus tumor tissue (log2 FC = −1.847, t-test p < 0.001).
This table shows molecular features associated with HMGN2P19 in patient tissues and cancer cell lines. In patient samples, HMGN2P19 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
